Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

A Novel GUCY2C-CD3 T cell Engaging Bispecific construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.

Mathur D, Root AR, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, Kearney JC, Lucas J, Guffroy M, Golas J, Rohde CM, Stevens C, Kamperschroer C, Kelleher K, Lawrence-Henderson RF, Upeslacis E, Yao J, Narula J, LaVallie ER, Fernandez DR, Buetow BS, Rosfjord E, Bloom L, King LE, Tchistiakova L, Nguyen A, Sapra P.

Clin Cancer Res. 2020 Jan 29. pii: clincanres.3275.2019. doi: 10.1158/1078-0432.CCR-19-3275. [Epub ahead of print]

2.

Erythroferrone inhibits the induction of hepcidin by BMP6.

Arezes J, Foy N, McHugh K, Sawant A, Quinkert D, Terraube V, Brinth A, Tam M, LaVallie ER, Taylor S, Armitage AE, Pasricha SR, Cunningham O, Lambert M, Draper SJ, Jasuja R, Drakesmith H.

Blood. 2018 Oct 4;132(14):1473-1477. doi: 10.1182/blood-2018-06-857995. Epub 2018 Aug 10.

3.

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.

Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O'Sullivan C, Cummins E, Lambert M, Sheehan AD, Ma W, Gatto S, Kerns K, Lam K, D'Antona AM, Zhu L, Brady WA, Benard S, King A, He T, Racie L, Arai M, Barrett D, Stochaj W, LaVallie ER, Apgar JR, Svenson K, Mosyak L, Yang Y, Chichili GR, Liu L, Li H, Burke S, Johnson S, Alderson R, Finlay WJJ, Lin L, Olland S, Somers W, Bonvini E, Gerber HP, May C, Moore PA, Tchistiakova L, Bloom L.

Antibodies (Basel). 2016 Mar 4;5(1). pii: E6. doi: 10.3390/antib5010006.

4.

A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).

Tu C, Terraube V, Tam AS, Stochaj W, Fennell BJ, Lin L, Stahl M, LaVallie ER, Somers W, Finlay WJ, Mosyak L, Bard J, Cunningham O.

J Biol Chem. 2016 Jan 15;291(3):1267-76. doi: 10.1074/jbc.M115.688010. Epub 2015 Oct 29.

5.

Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-β.

Kuai J, Mosyak L, Brooks J, Cain M, Carven GJ, Ogawa S, Ishino T, Tam M, Lavallie ER, Yang Z, Ponsel D, Rauchenberger R, Arch R, Pullen N.

Biochemistry. 2015 Mar 17;54(10):1918-29. doi: 10.1021/bi5015425. Epub 2015 Mar 6.

PMID:
25707433
6.

An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition.

Shih HH, Tu C, Cao W, Klein A, Ramsey R, Fennell BJ, Lambert M, Ní Shúilleabháin D, Autin B, Kouranova E, Laxmanan S, Braithwaite S, Wu L, Ait-Zahra M, Milici AJ, Dumin JA, LaVallie ER, Arai M, Corcoran C, Paulsen JE, Gill D, Cunningham O, Bard J, Mosyak L, Finlay WJ.

J Biol Chem. 2012 Dec 28;287(53):44425-34. doi: 10.1074/jbc.M112.415935. Epub 2012 Nov 12.

7.

Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure.

Goltsman I, Wang X, Lavallie ER, Diblasio-Smith EA, Ovcharenko E, Hoffman A, Abassi Z, Feuerstein GZ, Winaver J.

Circ Heart Fail. 2011 May;4(3):345-54. doi: 10.1161/CIRCHEARTFAILURE.110.960179. Epub 2011 Mar 11.

PMID:
21398416
8.

A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia.

Christaki E, Opal SM, Keith JC Jr, Kessimian N, Palardy JE, Parejo NA, Tan XY, Piche-Nicholas N, Tchistiakova L, Vlasuk GP, Shields KM, Feldman JL, Lavallie ER, Arai M, Mounts W, Pittman DD.

Shock. 2011 May;35(5):492-8. doi: 10.1097/SHK.0b013e31820b2e1c.

PMID:
21263385
9.

Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.

Wang X, Liu X, Zhan Y, Lavallie ER, Diblasio-Smith L, Collins-Racie L, Mounts WM, Rutkowski JL, Xu X, Goltsman I, Abassi Z, Winaver J, Feuerstein GZ.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):820-9. doi: 10.1124/jpet.110.167635. Epub 2010 Jun 2.

PMID:
20519551
10.

Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood.

Arai M, Jain S, Weaver AA, Hill AA, Guo Y, Bree AG, Smith MF Jr, Allen SW, LaVallie ER, Young D, Bloom L, Adkins K, O'Toole M.

J Transl Med. 2010 May 28;8:51. doi: 10.1186/1479-5876-8-51.

11.

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

Guo Y, Hill AA, Ramsey RC, Immermann FW, Corcoran C, Young D, Lavallie ER, Ryan M, Bechard T, Pfeifer R, Warner G, Bologna M, Bloom L, O'Toole M.

J Transl Med. 2010 May 26;8:50. doi: 10.1186/1479-5876-8-50.

12.

LXR modulation blocks prostaglandin E2 production and matrix degradation in cartilage and alleviates pain in a rat osteoarthritis model.

Li N, Rivéra-Bermúdez MA, Zhang M, Tejada J, Glasson SS, Collins-Racie LA, Lavallie ER, Wang Y, Chang KC, Nagpal S, Morris EA, Flannery CR, Yang Z.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3734-9. doi: 10.1073/pnas.0911377107. Epub 2010 Feb 3.

13.

Identification of a novel HtrA1-susceptible cleavage site in human aggrecan: evidence for the involvement of HtrA1 in aggrecan proteolysis in vivo.

Chamberland A, Wang E, Jones AR, Collins-Racie LA, LaVallie ER, Huang Y, Liu L, Morris EA, Flannery CR, Yang Z.

J Biol Chem. 2009 Oct 2;284(40):27352-9. doi: 10.1074/jbc.M109.037051. Epub 2009 Aug 5.

14.

Measurement of myostatin concentrations in human serum: Circulating concentrations in young and older men and effects of testosterone administration.

Lakshman KM, Bhasin S, Corcoran C, Collins-Racie LA, Tchistiakova L, Forlow SB, St Ledger K, Burczynski ME, Dorner AJ, Lavallie ER.

Mol Cell Endocrinol. 2009 Apr 10;302(1):26-32. doi: 10.1016/j.mce.2008.12.019. Epub 2009 Jan 21.

PMID:
19356623
15.

LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

Quinet EM, Basso MD, Halpern AR, Yates DW, Steffan RJ, Clerin V, Resmini C, Keith JC, Berrodin TJ, Feingold I, Zhong W, Hartman HB, Evans MJ, Gardell SJ, DiBlasio-Smith E, Mounts WM, LaVallie ER, Wrobel J, Nambi P, Vlasuk GP.

J Lipid Res. 2009 Dec;50(12):2358-70. doi: 10.1194/jlr.M900037-JLR200. Epub 2009 Mar 24.

16.

Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage: reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis.

Collins-Racie LA, Yang Z, Arai M, Li N, Majumdar MK, Nagpal S, Mounts WM, Dorner AJ, Morris E, LaVallie ER.

Osteoarthritis Cartilage. 2009 Jul;17(7):832-42. doi: 10.1016/j.joca.2008.12.011. Epub 2009 Jan 19.

17.

Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells.

DiBlasio-Smith EA, Arai M, Quinet EM, Evans MJ, Kornaga T, Basso MD, Chen L, Feingold I, Halpern AR, Liu QY, Nambi P, Savio D, Wang S, Mounts WM, Isler JA, Slager AM, Burczynski ME, Dorner AJ, LaVallie ER.

J Transl Med. 2008 Oct 16;6:59. doi: 10.1186/1479-5876-6-59.

18.

Use of ex vivo systems for biomarker discovery.

Lavallie ER, Dorner AJ, Burczynski ME.

Curr Opin Pharmacol. 2008 Oct;8(5):647-53. doi: 10.1016/j.coph.2008.08.003. Epub 2008 Sep 19. Review.

PMID:
18771752
19.

Production of recombinant proteins in Escherichia coli.

LaVallie ER.

Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.1. doi: 10.1002/0471140864.ps0501s00.

PMID:
18429175
20.

A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.

Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR.

Ann Neurol. 2008 May;63(5):561-71. doi: 10.1002/ana.21338.

PMID:
18335515
21.

Enzymatic and chemical cleavage of fusion proteins.

LaVallie ER, McCoy JM, Smith DB, Riggs P.

Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.4B. doi: 10.1002/0471142727.mb1604bs28.

PMID:
18265131
22.

Involvement of protein kinase Czeta in interleukin-1beta induction of ADAMTS-4 and type 2 nitric oxide synthase via NF-kappaB signaling in primary human osteoarthritic chondrocytes.

Chockalingam PS, Varadarajan U, Sheldon R, Fortier E, LaVallie ER, Morris EA, Yaworsky PJ, Majumdar MK.

Arthritis Rheum. 2007 Dec;56(12):4074-83.

23.

Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5.

Mosyak L, Georgiadis K, Shane T, Svenson K, Hebert T, McDonagh T, Mackie S, Olland S, Lin L, Zhong X, Kriz R, Reifenberg EL, Collins-Racie LA, Corcoran C, Freeman B, Zollner R, Marvell T, Vera M, Sum PE, Lavallie ER, Stahl M, Somers W.

Protein Sci. 2008 Jan;17(1):16-21. Epub 2007 Nov 27.

24.

Protein kinase Czeta is up-regulated in osteoarthritic cartilage and is required for activation of NF-kappaB by tumor necrosis factor and interleukin-1 in articular chondrocytes.

LaVallie ER, Chockalingam PS, Collins-Racie LA, Freeman BA, Keohan CC, Leitges M, Dorner AJ, Morris EA, Majumdar MK, Arai M.

J Biol Chem. 2006 Aug 25;281(34):24124-37. Epub 2006 Jun 23.

25.

A novel approach to identifying beta-secretase inhibitors: bis-statine peptide mimetics discovered using structure and spot synthesis.

Bridges KG, Chopra R, Lin L, Svenson K, Tam A, Jin G, Cowling R, Lovering F, Akopian TN, DiBlasio-Smith E, Annis-Freeman B, Marvell TH, LaVallie ER, Zollner RS, Bard J, Somers WS, Stahl ML, Kriz RW.

Peptides. 2006 Jul;27(7):1877-85. Epub 2006 Mar 30.

PMID:
16574278
26.

Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18.

Zeng W, Corcoran C, Collins-Racie LA, Lavallie ER, Morris EA, Flannery CR.

Biochim Biophys Acta. 2006 Mar;1760(3):517-24. Epub 2006 Feb 17.

PMID:
16507336
27.

A neurogenomics approach to gene expression analysis in the developing brain.

Jensen P, Magdaleno S, Lehman KM, Rice DS, Lavallie ER, Collins-Racie L, McCoy JM, Curran T.

Brain Res Mol Brain Res. 2004 Dec 20;132(2):116-27.

PMID:
15582152
28.

ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage.

Collins-Racie LA, Flannery CR, Zeng W, Corcoran C, Annis-Freeman B, Agostino MJ, Arai M, DiBlasio-Smith E, Dorner AJ, Georgiadis KE, Jin M, Tan XY, Morris EA, LaVallie ER.

Matrix Biol. 2004 Jul;23(4):219-30.

PMID:
15296936
29.

Effect of adenovirus-mediated overexpression of bovine ADAMTS-4 and human ADAMTS-5 in primary bovine articular chondrocyte pellet culture system.

Arai M, Anderson D, Kurdi Y, Annis-Freeman B, Shields K, Collins-Racie LA, Corcoran C, DiBlasio-Smith E, Pittman DD, Dorner AJ, Morris E, LaVallie ER.

Osteoarthritis Cartilage. 2004 Aug;12(8):599-613.

30.

Using bio-panning of FLITRX peptide libraries displayed on E. coli cell surface to study protein-protein interactions.

Lu Z, LaVallie ER, McCoy JM.

Methods Mol Biol. 2003;205:267-80. No abstract available.

PMID:
12491893
31.

Thioredoxin and related proteins as multifunctional fusion tags for soluble expression in E. coli.

LaVallie ER, DiBlasio-Smith EA, Collins-Racie LA, Lu Z, McCoy JM.

Methods Mol Biol. 2003;205:119-40. No abstract available.

PMID:
12491883
32.

Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites.

Flannery CR, Zeng W, Corcoran C, Collins-Racie LA, Chockalingam PS, Hebert T, Mackie SA, McDonagh T, Crawford TK, Tomkinson KN, LaVallie ER, Morris EA.

J Biol Chem. 2002 Nov 8;277(45):42775-80. Epub 2002 Aug 28.

33.

ADAMTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloproteinase site (Asn341-Phe342) in the aggrecan interglobular domain.

Westling J, Fosang AJ, Last K, Thompson VP, Tomkinson KN, Hebert T, McDonagh T, Collins-Racie LA, LaVallie ER, Morris EA, Sandy JD.

J Biol Chem. 2002 May 3;277(18):16059-66. Epub 2002 Feb 19.

34.

In situ hybridization screen in zebrafish for the selection of genes encoding secreted proteins.

Crosier PS, Bardsley A, Horsfield JA, Krassowska AK, Lavallie ER, Collins-Racie LA, Postlethwait JH, Yan YL, McCoy JM, Crosier KE.

Dev Dyn. 2001 Dec;222(4):637-44.

35.

Cloning and expression of a novel cysteine-rich secreted protein family member expressed in thyroid and pancreatic mesoderm within the chicken embryo.

Smith DM, Collins-Racie LA, Marigo VA, Roberts DJ, Davis NM, Hartmann C, Schweitzer R, LaVallie ER, Gamer L, McCoy J, Tabin CJ.

Mech Dev. 2001 Apr;102(1-2):223-6.

36.

Thioredoxin as a fusion partner for production of soluble recombinant proteins in Escherichia coli.

LaVallie ER, Lu Z, Diblasio-Smith EA, Collins-Racie LA, McCoy JM.

Methods Enzymol. 2000;326:322-40. No abstract available.

PMID:
11036651
37.

derrière: a TGF-beta family member required for posterior development in Xenopus.

Sun BI, Bush SM, Collins-Racie LA, LaVallie ER, DiBlasio-Smith EA, Wolfman NM, McCoy JM, Sive HL.

Development. 1999 Apr;126(7):1467-82.

38.

A plasmid expression system for quantitative in vivo biotinylation of thioredoxin fusion proteins in Escherichia coli.

Smith PA, Tripp BC, DiBlasio-Smith EA, Lu Z, LaVallie ER, McCoy JM.

Nucleic Acids Res. 1998 Mar 15;26(6):1414-20.

39.

A genetic selection for isolating cDNAs encoding secreted proteins.

Jacobs KA, Collins-Racie LA, Colbert M, Duckett M, Golden-Fleet M, Kelleher K, Kriz R, LaVallie ER, Merberg D, Spaulding V, Stover J, Williamson MJ, McCoy JM.

Gene. 1997 Oct 1;198(1-2):289-96.

PMID:
9370294
40.

Histidine patch thioredoxins. Mutant forms of thioredoxin with metal chelating affinity that provide for convenient purifications of thioredoxin fusion proteins.

Lu Z, DiBlasio-Smith EA, Grant KL, Warne NW, LaVallie ER, Collins-Racie LA, Follettie MT, Williamson MJ, McCoy JM.

J Biol Chem. 1996 Mar 1;271(9):5059-65.

41.

Production of a recombinant bovine enterokinase catalytic subunit in the methylotrophic yeast Pichia pastoris.

Vozza LA, Wittwer L, Higgins DR, Purcell TJ, Bergseid M, Collins-Racie LA, LaVallie ER, Hoeffler JP.

Biotechnology (N Y). 1996 Jan;14(1):77-81.

PMID:
9636316
42.

Gene fusion expression systems in Escherichia coli.

LaVallie ER, McCoy JM.

Curr Opin Biotechnol. 1995 Oct;6(5):501-6. Review.

PMID:
7579661
43.

Production of recombinant bovine enterokinase catalytic subunit in Escherichia coli using the novel secretory fusion partner DsbA.

Collins-Racie LA, McColgan JM, Grant KL, DiBlasio-Smith EA, McCoy JM, LaVallie ER.

Biotechnology (N Y). 1995 Sep;13(9):982-7.

PMID:
9636275
44.
45.

Cloning and functional expression of a cDNA encoding the catalytic subunit of bovine enterokinase.

LaVallie ER, Rehemtulla A, Racie LA, DiBlasio EA, Ferenz C, Grant KL, Light A, McCoy JM.

J Biol Chem. 1993 Nov 5;268(31):23311-7.

46.

A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm.

LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, McCoy JM.

Biotechnology (N Y). 1993 Feb;11(2):187-93.

PMID:
7763371

Supplemental Content

Loading ...
Support Center